Biopharmaceuticals

Nabi Biopharmaceuticals Announces Share Repurchase Program

Published in Drug Law Weekly, December 18th, 2007

Nabi Biopharmaceuticals (NASDAQ:NABI) announced that its Board of Directors has approved the repurchase of up to $65 million of the Company's outstanding common shares in the open market or in privately negotiated transactions. This share repurchase program includes the $3.1 million outstanding balance from the $5 million share repurchase program that the company announced in 2001.

"This repurchase program is the right thing to do for our shareholders and this is the right time to do it," said Dr. Leslie Hudson, Interim President and Chief Executive Officer of Nabi. "This is a first step. It not only reflects our continuing commitment to maximize shareholder value but...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2007-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry